Cogent Biosciences (COGT) Total Liabilities (2017 - 2026)

Cogent Biosciences (COGT) has 10 years of Total Liabilities data on file, last reported at $295.3 million in Q1 2026.

• On a quarterly basis, Total Liabilities rose 355.71% year-over-year to $295.3 million in Q1 2026; TTM through Mar 2026 was $295.3 million, a 355.71% increase from a year earlier, with the FY2025 full-year figure at $301.2 million, up 320.65% from the prior year.
• Total Liabilities for Q1 2026 stood at $295.3 million, down from $301.2 million in the prior quarter.
• Over the last five years, Total Liabilities for COGT reached as high as $301.2 million in Q4 2025 and fell as low as $19.0 million in Q1 2022.
• Historically, Total Liabilities has averaged $88.2 million across 5 years, with a median of $55.6 million in 2023.
• Across the five-year window, Total Liabilities fell 5.84% in 2023 and soared 355.71% in 2026, its largest moves.
• Year by year, Total Liabilities stood at $45.1 million in 2022, then increased by 23.43% to $55.6 million in 2023, then increased by 28.72% to $71.6 million in 2024, then jumped by 320.65% to $301.2 million in 2025, then dropped by 1.97% to $295.3 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $295.3 million in Q1 2026, $301.2 million in Q4 2025, and $123.5 million in Q3 2025.